Resources

Providing the best advocacy resources for biosimilars.

Whether you are a patient, caregiver, medical professional, payer, policymaker, or you just want to know more about biosimilars, our resources will teach you everything you need to know. Browse through our list below to learn more, and feel free to contact us.

The Biosimilars
Patient Resource Center

The Biosimilars Patient Resource Center is a convenient site for answers to your pressing questions about biosimilar medicines.

Whether you are a current or potential biosimilar or biologics patient, a caregiver, a medical professional, a policymaker, or if you just want to know more about biosimilars, the Biosimilars Patient Resource Center has information you can use.

The Biosimilars Handbook

The Biosimilars Handbook is the premier resource for biosimilar education.

Choose from one of four different tracks below – or check out our additional suggested resources – to learn how biosimilars and interchangeable biologic products can decrease costs and increase access to lifesaving medicines. we’re advocating for right now, and make your voice heard to get these policies across the finish line.

For Patients and Caregivers

Biosimilar Medicines Bring New Optimism on RA Awareness Day

Patients Increasingly Rely on Oncology Biosimilar Medicines

Biosimilar Medicines Equal More Accessible Care for America’s Patients

For Medical Professionals

AAM Annual Savings Report – Biosimilars and Bending the Cost Curve

Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption

FDA Biosimilars Approvals

For Payers

AAM Annual Savings Report – Biosimilars and Bending the Cost Curve

Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption

New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption

For Policymakers

Build Back Better Negotiation Framework Discourages Biosimilar Competition

The U.S. Generic & Biosimilar Medicines Savings Report

Increase Patient Access to Lower-Cost Biosimilar Medicines

Join the
Biosimilars Movement

Top Biosimilar Resources

Biosimilar Development

Biosimilars 101

Biosimilars are a safe, effective, and more affordable option for many patients who rely on biologic treatments.

Doctor helping patient

FDA Biosimilars Approvals

Find an up-to-date list of FDA-approved biosimilars and launches.

2022 U.S. Generic and Biosimilar Medicines Savings Report

This annual report is produced by the Institute for Human Data Science (IQVIA), the standard-bearer for measuring data, pharmaceutical use and spending in the United States.

Interchangeability 101 – Biosimilars and Interchangeable Biologics

This white board video from the Biosimilars Council walks through the basics of interchangeability and why biosimilars and interchangeable biologics are more than acceptable replacements for brand biologics.

Other Resources

  • All
  • Backgrounder
  • Biosimilars Bulletin
  • Blog
  • Council Resource
  • Event
  • Handbook
  • Infographic
  • Issue Brief
  • Member Spotlight
  • Partner Resource
  • Policy Recommendation
  • Press Release
  • Report
  • Video
  • Whitepapers

2022 U.S. Generic and Biosimilar Savings Report: Biosimilars Deliver on Their Promise

The 2022 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »

Biosimilars Bulletin | August 2022

A Note from Biosimilars Council Executive Director Craig Burton Last month, we witnessed the final passage and enactment of the... Read more »

Biosimilars Bulletin | July 2022

A Note from Biosimilars Council Executive Director Craig Burton As we write this, the Senate is actively considering the Inflation... Read more »

Health Care Professionals’ Perspectives are Essential to Greater Biosimilar Adoption

Since the first biosimilar was approved in the U.S. in 2015, these life savings therapies have provided nearly $13 billion... Read more »
Congress considers BBB Drug pricing negotiation

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However,... Read more »
Biosimilar Bulletin June 2022, doctor advising patient.

Biosimilars Bulletin | June 2022

A Note from Biosimilars Council Executive Director Craig Burton This month, both chambers of Congress made progress in advancing legislation... Read more »
Biosimilars help patients have more accessible care infographic

Biosimilar Medicines Equal More Accessible Care for Patients

Biosimilars are safe, effective, FDA-approved medicines used to treat diseases at lower costs than brand-name biologics. To date, biosimilars been used... Read more »
Biosimilars patient resource center, bulletin

Biosimilars Bulletin | May 2022

A Note from Former Executive Director Christine Simmon  As many of you have already heard, May was my last month... Read more »

Increase Patient Access to Lower-Cost Biosimilar Medicines

In 2010, Congress established the regulatory pathway which ultimately led to the first FDA-approved biosimilar becoming available five years later.... Read more »
The Federal Trade Commission

AAM Calls for Federal Trade Commission to Investigate PBM Business Practices

On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to... Read more »
Biosimilars Patient Resource Center

Everything You Need to Know About Biosimilars – All in One Place

Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness... Read more »
Doctor helping biosimilar patient

Biosimilars Bulletin | April 2022

A Note from Biosimilars Council Executive Director Christine Simmon Biosimilar adoption continues to steadily grow and reach new patients with... Read more »

Biosimilars Bulletin | March 2022

A Note from Biosimilars Council Executive Director Christine Simmon As we close out Women’s History Month, I would like to... Read more »

HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many PBMs... Read more »
Biosimilars helping patients

Treating Ulcerative Colitis, and Enjoying a Slice or Two

Greg, 37, of Los Angeles, CA., spends most of his time hiking, running and lifting weights, but his greatest passion... Read more »
Biosimilars Helping patient

Singing, Dancing and Taking Care of Herself with Biosimilars

Eileen, 28, lives in New York City and is pursuing her dream of a career in musical theater. Her stage... Read more »
Biosimilar law policy

BsUFA Reauthorization and Modernization Is the Key to a Healthy Biosimilar Market

This year, Congress will consider legislation that codifies performance goals for the review of drug applications by the U.S. Food... Read more »

Biosimilars Bulletin | February 2022

A Note from Biosimilars Council Executive Director Christine Simmon Happily, members of the Biosimilars Council and AAM were able to... Read more »

Access! 2022 Conference Recap

February 14-16, AAM and its Biosimilars Council welcomed attendees to Orlando, Florida for Access! 2022, the generics and biosimilars industry’s... Read more »
Biosimilars in 2022

Increase Patient Access to Biosimilars in 2022

Last year was full of exciting developments for patients who rely on biosimilars. Here’s a look at what we’re working... Read more »
Rheumatoid Arthritis awareness

Biosimilar Medicines Bring New Optimism on RA Awareness Day

On February 2 we mark Rheumatoid Arthritis (RA) Awareness Day and shine a light on the roughly 1.5 million Americans... Read more »

Your Biosimilars Bulletin | 2021 Year in Review

A Note from Biosimilars Council Executive Director Christine Simmon 2021 proved to be an eventful year for the biosimilars community,... Read more »

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers

This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1Findings such as these, paired with... Read more »

Biosimilars Bulletin | November 2021

A Note from Biosimilars Council Executive Director Christine Simmon The second annual Global Biosimilars Week proved a great way to... Read more »

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations

The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines.... Read more »

GRx+Biosims 2021 Conference Recap

AAM’s 2021 GRx+Biosims conference has officially come to a close, and by all accounts it delivered on its promise to... Read more »

Biosimilars Bulletin | October 2021

A Note from Biosimilars Council Executive Director Christine Simmon This month, the Biosimilars Council announced the release of AAM’s 2021... Read more »

Patients Increasingly Rely on Oncology Biosimilar Medicines

Biosimilar medicines are increasingly becoming an essential fixture in health care, reducing prices and increasing patient access. This is especially... Read more »

AAM Annual Savings Report – Biosimilars and Bending the Cost Curve

Since the enactment of the Biologics Price Competition and Innovation Act in 2010, patients with complex disease have been eager... Read more »

2021 U.S. Generic and Biosimilar Medicines Savings Report: The Promise of Biosimilars

The 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, proves that the promise of biosimilars is... Read more »
Biosimilar information

Biosimilars Bulletin | September 2021

A Note from Biosimilars Council Executive Director Christine Simmon September was an exciting month, as we announced the topline findings... Read more »
Approved Biosimilars

FDA Biosimilars Approvals

FDA Biosimilars Approvals BiosimilarApproved Launched AVASTIN (BEVACIZUMAB) Alymsy (bevacizumab-maly)Apr-22Oct-22 Mvasi (bevacizumab-awwb)Sep-17Jul-19 Zirabev (bevacizumab-bvzr)Jun-19Dec-19 Vegzelma, Celltrion (bevacizumab-adcd)Sep-22 ENBREL (ETANERCEPT) Erelzi (etanercept-szzs)Aug-16... Read more »
Biosimilar information

Biosimilars Bulletin | August 2021

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »

Biosimilars Bulletin | July 2021

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »
patient access to biosimilars

Increase Patient Access to Lower-Cost Biosimilar Medicines

Since the biosimilars pathway (BPCIA) was established in 2010, 30* biosimilars have been approved. However, due to significant barriers to... Read more »

Biosimilars Bulletin | June 2021

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry, including policy movement, educational... Read more »
The Biosimilars Council - Doctors with hands in the middle

Organizations Thank Rep. Schrader, Kinzinger for Introducing the BIOSIM Act

Today, a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups sent a letter thanking... Read more »

Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption

Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the… Read more »

Biosimilar Medicines Equal More Accessible Care for America’s Patients

In recent years, significant attention has been given to the advent of biosimilars, a new class of medicines approved by... Read more »
Akaimi, 44, San Antonio, TX | Leukemia

Akaimi Is Leading a Creative Lifestyle

As a single mother, a new grandmother and emerging artist, Akaimi, 44, of San Antonio, TX,  has an active and creative... Read more »

IQVIA Report Highlights Options to Boost U.S. Provider Use of Biosimilars

Biosimilars were first introduced in the United States about five years ago to treat patients with various medical conditions including... Read more »
Doctor meets with diabetic senior woman at medical appointment

The Biosimilars Council Applauds Reintroduction of the Bipartisan BIOSIM Act

WASHINGTON, D.C. (April 23, 2021) — The Biosimilars Council, representing leading developers of biosimilar medicines, strongly supports the reintroduction, and... Read more »

Access! 2021 Is Coming. Here’s What You Need to Know

Access!, AAM’s annual meeting for the generics and biosimilars industry, brings policymakers, influential speakers and industry leaders together to share... Read more »

New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption

Since the first biosimilar launched in the U.S. market five years ago, the U.S. Food and Drug Administration (FDA) has... Read more »

AAM Report: Securing Sustainable Markets

The first in a series of papers, this paper examines the challenges to market sustainability for generic and biosimilar medicines... Read more »
biosimilars news january 2021

Biosimilars Bulletin | January 2021

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
world cancer day

Cancer Costs and Options for Care in the United States

In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately... Read more »
biosimilars news december 2020

Biosimilars Bulletin | December 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
biosimilars facts

Biosimilars Facts

Biosimilar medicines are safe, effective alternative versions of existing brand biologic medicines (known as “reference products”) with scientifically comparable quality, safety... Read more »
helen relies on biosimilars

Helen Knows She Can Rely on Biosimilars

Diagnosed in her late twenties with incurable stage four non-Hodgkin lymphoma, Helen, now 41 and a wife and mother of... Read more »
biosimilars news november 2020

Biosimilars Bulletin | November 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
grx+biosims 2020

GRx+Biosims 2020 Conference Wrap-Up Blog

We’ve just completed this year’s GRx+Biosims 2020, the premier scientific and regulatory event for the U.S. generics and biosimilars industries,... Read more »
global biosimilars week

Biosimilars Council Joins IGBA in Celebrating Global Biosimilars Week

Biosimilars are critical to the discussion around health care and its rising costs, as they have the potential to save... Read more »
United States Courthouse Close Up view

Affordable Care Act and the Future of Biosimilars

Today, the U.S. Supreme Court will hear arguments on the constitutionality of the Affordable Care Act (ACA). Although the case... Read more »
biosimilars news october 2020

Biosimilars Bulletin | October 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
ten years of biosimilars

Ten Years of Biosimilars in the U.S.

The Biologics Price Competition and Innovation Act of 2010 (BPCIA) provides a framework for biosimilars approval, adoption and access in... Read more »
biosimilars help cancer patients

Biosimilars Can Help Cancer Patients

There are approximately 1.7 million new cases of cancer in the United States each year. Patients rely on FDA-approved medications... Read more »
biosimilars bulletin september 2020

Biosimilars Bulletin | September 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »

Jeni Got Her Life Back, Thanks to a Biosimilar

In 2019, Jeni Doerr finally received a diagnosis for her recent illnesses – pancolitis. Doerr, 35, from Newhall, CA, is... Read more »
increasing access to biosimilars act

Patent Abuse Blocks Patient Access to Needed Biosimilars

Biosimilar developers must combat several obstacles in bringing a product to market, including patent litigations like this, while brand companies... Read more »
Biosimilars News May 2020

How a Biosimilar is Developed

Before biologic drugs are ready to be used by patients, scientists and providers spend years developing, researching, and testing them... Read more »
twitter chat

Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (BioDrugs), the International... Read more »
biosimilars news january 2020

Advocacy for Patient Access to Biosimilars

According to a report on biosimilars cost savings in the U.S., biosimilars could lead to over $54 billion in savings... Read more »
Approved Biosimilars

What are biosimilars?

Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic currently on the market. But what does that short definition of a biosimilar actually mean?... Read more »
Biosimilars News August 2020

Biosimilars Bulletin | August 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
Biosimilars News July 2020

Biosimilars Bulletin | July 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
alternative to biologic medicines

Patients Have an Alternative to Expensive Biologic Medicines

Patients have an alternative to expensive biologic medicines. Biosimilars are FDA-approved alternatives to reference biologics – much like generic drugs... Read more »
biosimilars benefit everyone

Biosimilars Benefit Everyone

Biosimilars benefit everyone. Biosimilars are FDA-approved alternatives to reference biologics – much like generic drugs – that provide treatment options... Read more »
biosimilars in the pharmacy

Biosimilars In The Pharmacy

Biosimilars in the pharmacy benefit employers driving appropriate use and transparency. Despite the fact that less than 2 percent of... Read more »
Biosimilars news June 2020

Biosimilars Bulletin | June 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
Biosimilars News May 2020

Biosimilars Bulletin | May 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
europe's biosimilars market

Lessons for the United States on Europe’s Biosimilar Experience

Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions... Read more »
biosimilars news april 2020

Biosimilars Bulletin | April 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
Bulletin March

Biosimilars Bulletin | March 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
Resources

ERIC Launches Initiative to Understand Biosimilars Potential to Lower Health Care Costs

More than 180 million Americans receive health care benefits through their employer, with large employers paying more than 80 percent... Read more »
twitter chat

Biosimilars Bulletin | February 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »

Biosimilars Study Shows Massive State Savings Potential

According to a study released by Pacific Research Institute, biosimilars have the potential to bring significant savings to both state... Read more »

Physician Biosimilar Testimonials

“It is absolutely safe for a patient to switch from a biologic to a biosimilar because their qualities are similar.... Read more »
biosimilars news january 2020

Biosimilars Bulletin | January 2020

Each month, the Biosimilars Council sends a newsletter with the latest updates in the biosimilars industry including policy movement, educational... Read more »
biosimilars year in review

Biosimilars Council 2019 Year in Review

2019 was a whirlwind year for biosimilars, highlighted by a record 10 U.S. Food and Drug Administration (FDA) approvals and... Read more »
biosimilars in the united states

Biosimilars in the United States

Providing More Patients Greater Access to Lifesaving Medicines Biologics are innovative treatment options for patients affected by debilitating and life-threatening... Read more »

GRx+Biosims 2019 Conference: Advancing Biosimilars Access

Earlier this month the Association for Accessible Medicines (AAM) and its Biosimilars Council hosted the second annual GRx+Biosims Conference for... Read more »
GRx+Biosims 2019

Biosimilars Council Kicks Off GRx+Biosims 2019

The Association for Accessible Medicines (AAM) and its Biosimilars Council are eager for the start of this year’s GRx+Biosims conference... Read more »
increasing patient access to biosimilars

Hillel Cohen, PhD, of Sandoz on Increasing Patient Access to Biosimilars Through Stakeholder Engagement and Education

Sandoz, Inc. Executive Director of Scientific Affairs Hillel Cohen joins us to talk about the future of biosimilars in the... Read more »
Naming Biosimilars

Suffix vs No Suffix: Naming Biologics and Biosimilars

Biologics and biosimilars are both FDA-approved medicines that help patients treat or manage debilitating diseases. All biologic drugs, including biosimilars,... Read more »

FDA Releases New Biosimilars Education Materials for Patients

When it comes to ensuring medicines  — including biosimilars — are safe and effective for patients, the FDA remains the… Read more »

barriers to biosimilar adoption

Biosimilars Uptake Failure

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access... Read more »

Biosimilar Action Plan Report Card

In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). The plan detailed... Read more »

Will increased biosimilar use benefit the U.S. health system?

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »

Patent Abuse Blocks Access to Biosimilars for Patients

As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars... Read more »
are biosimilars safe

Are biosimilars safe?

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »

Announcing our Biosimilars Council “Member Spotlight” Series

Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. This summer, as part of our commitment to broad stakeholder education about... Read more »

Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »

what is a biosimilar

What is a biosimilar?

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »

Member Spotlight | Q&A with Hillel Cohen

Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Member Spotlight/Q&A Hillel P. Cohen, Ph.D., Executive Director, Scientific Affairs, Sandoz, Inc., is... Read more »

The Importance of Naming for Market Adoption of Biosimilars

Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Written by Hillel P. Cohen Biosimilars are a competitive, effective alternative for... Read more »
interchangeable insulin

Insulin Biosimilars White Paper

Insulin has been available to America’s diabetes patients for decades, and millions of patients rely on this medicine every day... Read more »

Insulin Biosimilars: Ensuring Access for America’s Diabetes Patients

Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their... Read more »

Chip Davis: “The Biosimilars Wave is Coming. Are Pharmacists Prepared?”

In a recent for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the... Read more »

Abandoning Biosimilars Leaves Savings on the Table and Patients in the Lurch

A recent series in Health Affairs questioned whether competition from biosimilar medicines is a viable path to providing relief from… Read more »

interchangeability vs biosimilar

Interchangeability 101 – Biosimilars & Interchangeable Biologics

Biosimilars are safe, effective medicines for patients that treat some of the most difficult-to-treat conditions such as psoriasis, rheumatoid arthritis... Read more »

Bipartisan Legislation Targets Patent Thickets, Supports Biosimilars Uptake

The Biologic Patent Transparency Act, introduced in March and sponsored by Senators Susan Collins (R-ME) and Tim Kaine (D-VA), would... Read more »

Biosimilars: A Science Success Story

The Biosimilars Council is proud to partner with the International Generic and Biosimilar Medicines Association (IGBA) to launch a new... Read more »
Biosimilars Council Recap of Access! 2019

Biosimilars Council Recap of Access! 2019

Earlier this month in New Orleans, the Association for Accessible Medicines and its Biosimilars Council hosted our annual Access! Conference. Attendees from... Read more »
Brand Efforts Seek to Limit Patient Access to Biosimilars

Brand Efforts Seek to Limit Patient Access to Biosimilars

Actions by branded companies to undermine proven safe, effective biosimilars hurt patients. U.S. Food & Drug Administration Commissioner Scott Gottlieb... Read more »

How a Biosimilar Reaches a Patient

Biosimilars are safe, effective, and competitive alternatives to expensive brand-name biologics that are used to treat serious chronic diseases, like... Read more »
Biosimilars Council - Biosimilars Approvals Speeding Up

FDA Approval of Biosimilars Picking Up Pace

On Friday, December 14, the U.S. Food and Drug Administration (FDA) announced its sixteenth biosimilar approval for biosimilar trastuzumab, a drug used in... Read more »
Biosimilars Education Course for Clinicians

New Resource: Biosimilars Education Course for Clinicians

The American Society of Hematology (ASH) has added to its eLearning platform a new educational course titled “Biosimilars: A New Era of Hematology/Oncology... Read more »
Stairs and columns in front of the United States Supreme Court in Washington DC.

Taking Steps to Increase Patient Access to Life Altering Biosimilar Medicines

The burden of high prescription medicine costs for America’s patients continues to drive much of the national health care conversation and... Read more »
Biosimilars Council - Pass the CREATES Act

Cleveland Clinic Chief Pharmacy Officer: Time to Pass the CREATES Act

Scott Knoer, M.S., Pharm.D, serves as Chief Pharmacy Officer for the Cleveland Clinic, one of the largest hospitals nationwide. In... Read more »
Frontiers for Public Health Study - Biologics

New Study: Pharmacist Involvement Key to Reducing Cost of Biologics

A recent Italian study published in Frontiers in Public Health examined the effect of including a pharmacist in the Department of Abdominal... Read more »
APhA - Biosimilars Council - Biosimilars Basics for Patients

Pharmacists: On the Front Lines of Biosimilar Education

Pharmacists are among the most trusted health care professionals in America. Millions of patients rely on their pharmacist for guidance... Read more »
Biosimilars Council - IQVIA Report - Advancing Biosimilar Sustainability in Europe

IQVIA Releases Report Detailing Sustainability of Biosimilars in European Markets

IQVIA, a leading healthcare research company, recently released a new report, “Advancing Biosimilar Sustainability in Europe,” which examines the status of biosimilars... Read more »

Drug Savings and Access Report Highlights

Ninety-three percent of generic prescription drugs are filled at $20 or less. Watch this video to learn about the benefits... Read more »

Biosimilar Medicines in the EU (from IGBA)

What is a biosimilar? How does the European Medicines Agency (EMA) work to ensure that these biological medicines are as... Read more »
Biosimilars Council - Renegotiated NAFTA Event

Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High

Friday, September 14, 2018 Noon–1:00 p.m. 1310 Longworth House Office Building Committee on House Administration Hearing Room On August 31,... Read more »
Biosimilars Council - AAM This Month - August - Pills Background

AAM This Month – August

The Biosimilars Council's parent organization, the Association for Accessible Medicines (AAM), is active in promoting education around a variety of... Read more »
Biosimilars Council - Doctor Writing Prescription

Health Organizations Pen Letter to FDA Encouraging Action on Interchangeability Guidance

Seventeen stakeholder groups representing a variety of healthcare industry’s sent a letter to FDA, urging greater clarity on interchangeability guidance... Read more »
Biosimilars Council - Doctors Standing Together

Biosimilars Council Joins Other North American Generic Drugmakers in Rejection of New Exclusivity Period for Biologics

This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
IGBA Position on Identification of Biological, including Biosimilar Medicines - Cover Image

IGBA’s Comprehensive Review of Global Naming Practices for Biologic Drugs

The International Generic and Biosimilars Medicines Association (IGBA) has released an in-depth review of global biosimilar and biologic drug naming... Read more »
The Biosimilars Council - Female Pharmacist with Customer

Biosimilars Basics for Patients (from APhA)

This brochure is an original publication of the American Pharmacists Association - a Biosimilars Council partner - and the full... Read more »
The Biosimilars Council - Understanding Biologic and Biosimilar Drugs

Understanding Biologic and Biosimilar Drugs (from ACS CAN)

This is a replication of an original post (Understanding Biologic and Biosimilar Drugs) on the Cancer Action Network of the... Read more »
The Biosimilars Council - U.S. Capitol Building at Sunset

Increasing Access to Treatment Options Through Biosimilar Legislation (from APhA)

This blog post was originally posted on the Cancer Action Network of the American Cancer Society and the full article... Read more »
Biosimilars Council - Doctor Shaking Hand of Patient

New Council Partnerships Boost Patient Understanding of Biosimilars’ Benefits

This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »

IGBA Position on Identification of Biological, including Biosimilar Medicines

Click the button below to download the International Generics & Biosimilars Association's (IGBA) 2018 PowerPoint update on facts and figures... Read more »
The Biosimilars Council - Seniors Sitting at a Meeting

Breaking Through on Biosimilars: Delivering More-Affordable, Innovative Medicines for America’s Patients

Please join us on Thursday, July 26th at noon for a lunch briefing hosted by the Association for Accessible Medicines (AAM)... Read more »

Biosimilars Action Plan: Balancing innovation and competition

Christine Simmon, Executive Director of AAM's Biosimilars Council, reacts to the recent release of FDA's Biosimilars Action Plan About the... Read more »
The Biosimilars Council - 2018 Access and Savings Report Cover Zoomed In

2018 Generic Drug Access & Savings in the U.S.

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
biosimilar myths vs facts

Myths vs. Facts: Learning the Truth About Biosimilars

The pharmaceutical industry can be complicated and with new medicines coming to market every day, it can be tough to... Read more »
The Biosimilars Council - Skyrocketing Drug Prices

Skyrocketing Drug Prices

Prescription drugs treat conditions and improve patient health. But when drug prices are too high, access to medicines becomes out... Read more »
The Biosimilars Council - Breaking Through on Biosimilars Whitepaper

White Paper: Breaking Through on Biosimilars

America’s patients who suffer from many complex and chronic diseases have promising new treatment options in biologic and specialty medicines.... Read more »
About the Biosimilars Council - T-cell background

The New Frontier for Improved Access to Medicines [Website]

Reading the Biosimilars Council Handbook is now easier than ever. Click on the image below to browse our interactive Handbook... Read more »
Developing a Robust Biosimilars Market in the U.S.

Developing a Robust Biosimilars Market in the U.S.

Biosimilars have the potential to improve quality of life for patients. If the right policies are put in place to... Read more »
Biosimilars Council - Large Meeting with Conference Attendees

The Biosimilars Council Congressional Briefing: Five Takeaways

Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion... Read more »
biosimilars - a safe and effective option

Biosimilars: A Safe & Effective Option for Patients

In the U.S., the FDA is approving more biosimilars and patients are benefitting from these new medicines. Access to these... Read more »
biosimilars - breaking down barriers infographic

Biosimilars: Breaking Down Barriers to Patient Access

Since it was created in 2007, the Food & Drug Administration’s (FDA’s) Risk Evaluation and Mitigation Strategies (REMS) has been... Read more »
About the Biosimilars Council - T-cell background

The New Frontier for Improved Access to Medicines [PDF Copy]

In addition to our interactive Handbook, you can also download a PDF copy of the Biosimilars Council's Handbook. Inside this... Read more »
Paving the Way for Biosimilars

Paving the Way for Biosimilars

Biosimilars are safe, effective alternative versions of existing biologic medicines (known as “reference products”) with scientifically comparable quality, safety and... Read more »
Patient Access Report: Biosimilars in the United States

Patient Access Report: Biosimilars in the U.S.

Biologics are medicines extracted from a variety of natural sources—human, animal or microorganism—and include a wide range of products such... Read more »
Biosimilars Council - Microscope Up Close

Misinformation on Biosimilars Undermines Patient and Prescriber Confidence

Science, Data and FDA Support the Safety and Efficacy of Biosimilars for Patients As the biosimilars market begins to expand... Read more »

Skyrocketing Brand Drug Prices

The average annual price of speciality drugs has tripled over the last ten years. Watch this video for information on... Read more »
The Biosimilars Council - GRxBiosims Event Banner

GRx+Biosims Conference

AAM listened to our members and conference attendees and has created the ultimate event for the industry. We combined all... Read more »
The Biosimilars Council - People Meeting Image

AAM Women in Health Policy Happy Hour

Thursday, April 19, 2018 – 5-7pm – 601 New Jersey Ave. NW Join The Biosimilars Council and the Association for... Read more »
Biosimilars Council - Bottles being filled

The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence

In response to the growing number of biosimilar approvals and increased acceptance of their safety and efficacy a number of... Read more »

Time to Pass the CREATES Act

The CREATESAct will help increase patient access to generic and biosimilar medicines. This video explainer provides background and information on... Read more »
Biosimilars Council - Pharmacists looking at Computer

Why Increasing Patient Awareness of Biosimilars Is Important

Today’s healthcare arsenal includes biological products, or biologics, that are used in the treatment, prevention or diagnosis of diseases and... Read more »
Biosimilars Council - FDA Website Screenshot

FDA’s Steps to Improve Biosimilars Access in 2017 and Beyond

2017 was a watershed year for patients seeking affordable alternatives to expensive biologic medicines . The number of FDA-approved biosimilars more... Read more »
Biosimilars Council - Doctor with Child Patient

Why Biosimilars Are Important for Patients

Since their first use in the 1980s, biologic medicines have grown to become an indispensable tool in modern medicine. Advancements... Read more »
The Biosimilars Council - Doctor discussing with happy patient

A Watershed Year for Biosimilars in the U.S.

For anyone following the nascent biosimilars market in the U.S., 2017 has been a busy year: the Centers for Medicare... Read more »
The Biosimilars Council - Doctor taking patient blood pressure

Mind the Gap: Realizing Savings and Increasing Patient Access to Biosimilars in Medicare Part D

Biosimilars hold great promise for patients seeking access to more affordable versions of critical medicines, but also for a health care system facing unsustainable, increasing costs. One of the most immediate challenges to biosimilars uptake in the United State sis the lack of […]

Medicare Part B Issue Brief

Biosimilars in Medicare Part B

It is the Biosimilars Council’s position that Congress established pass-through status to foster innovation and to remove financial barriers to... Read more »
Biosimilars Medicare Part D

Biosimilars Medicare Part D

Biosimilar medicines are safe, effective and affordable versions of costly brand biologics for the treatment of cancer, rheumatoid arthritis and... Read more »
The Biosimilars Council - Doctors Discussing in a Circle

Forging a Path: How We Are Leading on Access to Biosimilars

In the fast-paced world of health care, the role of the patient continues to evolve from passive to active. One of the most pressing issues patients face is the cost of their medications, which can serve as a significant barrier to access, especially for expensive brand-name biologic medicines[…]

The Biosimilars Council - Doctors Applauding

Leading on Biosimilars: 2017 AAM Biosimilars Council Conference Preview

Join us as we examine the promise of biosimilars in the United States and discuss how best to ensure patient... Read more »
The Biosimilars Council - Doctor with Stethoscope and pens

New Study: Biosimilars Earn the Trust of Health Insurers

This week, Avalere Health published new research that found 81% of health insurers are covering at least one of the... Read more »

2017 Generic Drug Access and Savings in the U.S. Report

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »

Event Recap: The Next Drugs: The Future for Biosimilars

On June 7th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Update on Biosimilars” at the Newseum in Washington, D.C. The third in a series of Atlantic biosimilars briefings underwritten by The Biosimilars Council […]

Biosimilars Council & The Atlantic: The Next Drugs: The Future for Biosimilars

Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings. But there are barriers […]

Biosimilars Factsheet: A Safe & Effective Option for Patients

Informative fact sheet listing the multitude of benefits of biosimilar medications. Includes useful statistics about the state of the industry.... Read more »
The Biosimilars Council - Table with Phones from Overhead

The Next Drugs: An Atlantic Policy Update on Biosimilars

Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars […]

Doctor forward with child patient behind

Supreme Court Hears Biosimilars Patent Case

The country has undergone a great deal of change from December to today – but one thing that has not changed is that Americans want action to bring down the price of prescription drugs. A recent Kaiser Health Tracking Poll showed that over 60% of Americans believe lowering the cost of […]

Recapping: The Future For Biosimilars (an Atlantic policy briefing)

On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the […]

The Next Drugs: An Atlantic Policy Briefing on Biosimilars

Underwritten by The Biosimilars Council The Atlantic gathered key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States. How does the Food and Drug Administration implement[…]

The Next Drugs: The Future for Biosimilars, An Atlantic Policy Briefing

Join The Atlantic as we gather key stakeholders to examine the future for biosimilars domestically and abroad. What impact will... Read more »

Stay Informed About The Latest Issues.

Subscribe to the monthly Biosimilars Bulletin.


Recent Tweets

Unable to load Tweets